These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32982167)

  • 21. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
    Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
    Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
    Choi HJ; Kim YJ; Lee S; Kim YS
    Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
    Yuan Q; Liang Q; Sun Z; Yuan X; Hou W; Wang Y; Wang H; Yu M
    Oncoimmunology; 2021; 10(1):1914954. PubMed ID: 34350059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

  • 30. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
    Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
    Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
    Benonisson H; Altıntaş I; Sluijter M; Verploegen S; Labrijn AF; Schuurhuis DH; Houtkamp MA; Verbeek JS; Schuurman J; van Hall T
    Mol Cancer Ther; 2019 Feb; 18(2):312-322. PubMed ID: 30381448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
    Taki S; Kamada H; Inoue M; Nagano K; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
    PLoS One; 2015; 10(12):e0144712. PubMed ID: 26678395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer.
    Lee BS; Kim HJ; Hwang JW; Cheong KH; Kim KA; Cha HY; Lee JM; Kim CH
    Ann Surg Oncol; 2016 Jun; 23(6):2046-53. PubMed ID: 26812910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.